Patents by Inventor Andrew Craig Donohue
Andrew Craig Donohue has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11787906Abstract: A drug-polymer conjugate, which is a copolymer of at least one monomer of formula (I): (I) where: X may be the same or different at each occurrence and represents a terminal functional group comprising an alkyne or an azide; Q is independently selected at each occurrence and may be present or absent and when present, represents a linking group; R is selected from the group consisting of linear or branched hydrocarbon, optionally substituted aryl and optionally substituted heteroaryl; D is a releasable drug selected from prostaglandins, ?-blockers and mixtures thereof; L is a linker group group; and at least one co-monomer of Formula III III J represents a linking functional group, n is 2 to 8, preferably 3 to 8; Y comprises a polyether of formula (ORa)m wherein Ra is independently ethylene, propylene and butylene and m is from 1 to 300 (preferably 2 to 300) and the polyether is in chain with one or more groups which are preferably selected from one or more of optionally substituted straight or branched C1 toType: GrantFiled: March 14, 2018Date of Patent: October 17, 2023Assignee: POLYACTIVA PTY LTDInventors: Stephen Lonsdale Birkett, Andrew Craig Donohue, Asha Marina D'Souza, Sarah Man Yee Ng, Adrian Sulistio, Russell John Tait, David Valade, Alan Naylor, Jason Watling, Carmen Vittoria Scullino
-
Patent number: 11696955Abstract: A polymer-prostaglandin conjugate comprising: a polymer backbone comprising a plurality of moieties of formula (I): where: T represents a triazole moiety; Q is independently selected at each occurrence and may be present or absent and when present represents a linking group; R is selected from the group consisting of linear or branched hydrocarbon; D is selected from prostaglandins; and L is a group of formula (II) wherein R5 is selected from hydrogen and C1 to C6 alkyl; (R) indicates the end of the group bonded to the R group; and (D) indicates the end of the group attached to the group D.Type: GrantFiled: December 23, 2021Date of Patent: July 11, 2023Assignee: POLYACTIVA PTY LTDInventors: Stephen Lonsdale Birkett, Andrew Craig Donohue, Asha Marina D'Souza, Sarah Man Yee Ng, Adrian Sulistio, Russell John Tait, David Valade, Alan Naylor, Jason Watling
-
Publication number: 20220401455Abstract: A drug-polymer conjugate, which is a copolymer of at least one monomer of formula (I) where: X may be the same or different at each occurrence and represents a terminal functional group comprising an alkyne or an azide; Q is independently selected at each occurrence and may be present or absent and when present, represents a linking group; R is selected from the group consisting of linear or branched hydrocarbon, optionally substituted aryl and optionally substituted heteroaryl; D is a releasable bicyclic prostaglandin; L is a linker group; and at least one co-monomer of Formula III J-(Y1-A)n, J represents a linking functional group, n is 2 to 8 preferably 3 to 8; Y1 comprises a polyether of formula (ORa)m wherein Ra is independently ethylene, propylene and butylene and m is from 1 to 300 (preferably 2 to 300) and the polyether is in chain with one or more groups which are preferably selected from one or more of optionally substituted straight or branched C1 to C10 alkylene, amino, ether, ester, amide, carbonType: ApplicationFiled: September 19, 2019Publication date: December 22, 2022Applicant: POLYACTIVA PTY LTDInventors: Stephen Lonsdale BIRKETT, Andrew Craig DONOHUE, Asha Marina D'SOUZA, Sarah Man Yee NG, Adrian SULISTIO, Russell John TAIT, David VALADE, Alan NAYLOR, Jason WATLING, Carmen Vittoria SCULLINO
-
Publication number: 20220388967Abstract: The present invention relates to phenyl amino pyrimidine compounds which are inhibitors of protein kinases including JAK kinases. In particular the compounds are selective for JAK2 kinases. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.Type: ApplicationFiled: April 20, 2022Publication date: December 8, 2022Applicant: Sierra Oncology, Inc.Inventors: Christopher John Burns, Andrew Craig Donohue, John Thomas Feutrill, Thao Lien Thi Nguyen, Andrew Frederick Wilks, Jun Zeng
-
Publication number: 20220226483Abstract: A polymer-prostaglandin conjugate comprising: a polymer backbone comprising a plurality of moieties of formula (I): where: T represents a triazole moiety; Q is independently selected at each occurrence and may be present or absent and when present represents a linking group; R is selected from the group consisting of linear or branched hydrocarbon; D is selected from prostaglandins; and L is a group of formula (II) wherein R5 is selected from hydrogen and C1 to C6 alkyl; (R) indicates the end of the group bonded to the R group; and (D) indicates the end of the group attached to the group D.Type: ApplicationFiled: December 23, 2021Publication date: July 21, 2022Applicant: POLYACTIVA PTY LTDInventors: Stephen Lonsdale BIRKETT, Andrew Craig DONOHUE, Asha Marina D'SOUZA, Sarah Man Yee NG, Adrian SULISTIO, Russell John TAIT, David VALADE, Alan NAYLOR, Jason WATLING
-
Patent number: 11207417Abstract: A polymer-prostaglandin conjugate comprising: a polymer backbone comprising a plurality of moieties of formula (I): where: T represents a triazole moiety; Q is independently selected at each occurrence and may be present or absent and when present represents a linking group; R is selected from the group consisting of linear or branched hydrocarbon; D is selected from prostaglandins; and L is a group of formula (II) wherein R5 is selected from hydrogen and C1 to C6 alkyl; (R) indicates the end of the group bonded to the R group; and (D) indicates the end of the group attached to the group D.Type: GrantFiled: March 14, 2018Date of Patent: December 28, 2021Assignee: POLYACTIVA PTY LTDInventors: Stephen Lonsdale Birkett, Andrew Craig Donohue, Asha Marina D'Souza, Sarah Man Yee Ng, Adrian Sulistio, Russell John Tait, David Valade, Alan Naylor, Jason Watling
-
Publication number: 20210309615Abstract: The present invention relates to phenyl amino pyrimidine compounds which are inhibitors of protein kinases including JAK kinases. In particular the compounds are selective for JAK2 kinases. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.Type: ApplicationFiled: December 7, 2015Publication date: October 7, 2021Inventors: Christopher John Burns, Andrew Craig Donohue, John Thomas Feutrill, Thao Lien Thi Nguyen, Andrew Frederick Wilks, Jun Zeng
-
Patent number: 10758626Abstract: The present invention relates in general to polymer-bioactive agent conjugates for delivering a bioactive agent to a subject. The polymer-bioactive agent conjugates contain triazole moieties in the polymer backbone and a bioactive moiety selected from quinolones, NSAIDs and mixtures thereof. The present invention also relates to methods for preparing the polymer conjugates using click cycloaddition chemical reactions, to monomer-bioactive agent conjugates suitable for preparing the polymer conjugates, and to pharmaceutical products comprising the polymer conjugates for the post-surgical care to treat or prevent infections, provide analgesia and treat inflammation.Type: GrantFiled: September 9, 2016Date of Patent: September 1, 2020Assignee: POLYACTIVA PTY LTDInventors: Stephen Lonsdale Birkett, Andrew Craig Donohue, Asha Marina D'Souza, Sarah Man Yee Ng, Adrian Sulistio, Russell John Tait, David Valade, Alan Naylor, Anton Blencowe
-
Publication number: 20200121798Abstract: A polymer-prostaglandin conjugate comprising: a polymer backbone comprising a plurality of moieties of formula (I): where: T represents a triazole moiety; Q is independently selected at each occurrence and may be present or absent and when present represents a linking group; R is selected from the group consisting of linear or branched hydrocarbon; D is selected from prostaglandins; and L is a group of formula (II) wherein R5 is selected from hydrogen and C1 to C6 alkyl; (R) indicates the end of the group bonded to the R group; and (D) indicates the end of the group attached to the group D.Type: ApplicationFiled: March 14, 2018Publication date: April 23, 2020Applicant: POLYACTIVA PTY LTDInventors: Stephen Lonsdale BIRKETT, Andrew Craig DONOHUE, Asha Marina D'SOUZA, Sara Man Yee NG, Adrian SULISTIO, Russell John TAIT, David VALADE, Alan NAYLOR, Jason WATLING
-
Publication number: 20200123322Abstract: A drug-polymer conjugate, which is a copolymer of at least one monomer of formula (I): (I) where: X may be the same or different at each occurrence and represents a terminal functional group comprising an alkyne or an azide; Q is independently selected at each occurrence and may be present or absent and when present, represents a linking group; R is selected from the group consisting of linear or branched hydrocarbon, optionally substituted aryl and optionally substituted heteroaryl; D is a releasable drug selected from prostaglandins, ?-blockers and mixtures thereof; L is a linker group group; and at least one co-monomer of Formula III III J represents a linking functional group, n is 2 to 8, preferably 3 to 8; Y comprises a polyether of formula (ORa)m wherein Ra is independently ethylene, propylene and butylene and m is from 1 to 300 (preferably 2 to 300) and the polyether is in chain with one or more groups which are preferably selected from one or more of optionally substituted straight or branched Ci toType: ApplicationFiled: March 14, 2018Publication date: April 23, 2020Applicant: POLYACTIVA PTY LTDInventors: Stephen Lonsdale BIRKETT, Andrew Craig DONOHUE, Asha Marina D'SOUZA, Sara Man Yee NG, Adrian SULISTIO, Russell John TAIT, David VALADE, Alan NAYLOR, Jason WATLING, Carmen Vittoria SCULLINO
-
Patent number: 10111886Abstract: The present invention relates in general to polymer-bioactive agent conjugates for delivering a bioactive agent to a subject. The polymer-bioactive agent conjugates contain triazole moieties in the polymer backbone and a bioactive moiety selected from prostaglandin analogues, .beta.-blockers and mixtures thereof. The present invention also relates to methods for preparing the polymer conjugates using click chemical reactions, to monomer-bioactive agent conjugates suitable for preparing the polymer conjugates, and to pharmaceutical products comprising the polymer conjugates for the treatment of glaucoma.Type: GrantFiled: February 17, 2017Date of Patent: October 30, 2018Assignee: POLYACTIVA PTY LTDInventors: Sarah Man Yee Ng, Andrew Craig Donohue, Russell John Tait, Stephen Lonsdale Birkett, Adrian Sulistio, Anton Blencowe
-
Patent number: 10113033Abstract: The present invention relates in general to polymer-bioactive agent conjugates for delivering a bioactive agent to a subject. The polymer-bioactive agent conjugates contain triazole moieties in the polymer backbone and a bioactive moiety comprising prostaglandin analogues. The present invention also relates to methods for preparing the polymer conjugates using click chemical reactions, to monomer-bioactive agent conjugates suitable for preparing the polymer conjugates, and to pharmaceutical products comprising the polymer conjugates for the treatment of glaucoma.Type: GrantFiled: March 14, 2017Date of Patent: October 30, 2018Assignee: POLYACTIVA PTY LTDInventors: Sarah Man Yee Ng, Andrew Craig Donohue, Russell John Tait, Stephen Lonsdale Birkett, Adrian Sulistio, Anton Blencowe, Alan Naylor
-
Publication number: 20180303948Abstract: The present invention relates in general to polymer-bioactive agent conjugates for delivering a bioactive agent to a subject. The polymer-bioactive agent conjugates contain triazole moieties in the polymer backbone and a bioactive moiety selected from quinolones, NSAIDs and mixtures thereof. The present invention also relates to methods for preparing the polymer conjugates using click cycloaddition chemical reactions, to monomer-bioactive agent conjugates suitable for preparing the polymer conjugates, and to pharmaceutical products comprising the polymer conjugates for the post-surgical care to treat or prevent infections, provide analgesia and treat inflammation.Type: ApplicationFiled: September 9, 2016Publication date: October 25, 2018Applicant: Polyactiva Pty LtdInventors: Stephen Lonsdale BIRKETT, Andrew Craig DONOHUE, Asha Marina D'SOUZA, Sara Man Yee NG, Adrian SULISTIO, Russell John TAIT, David VALADE
-
Patent number: 9968684Abstract: The invention relates to polymer-drug conjugate for delivering a substituted alkanoic acid non-steroidal anti-inflammatory drug (NSAID). The invention also relates to drug delivery systems comprising the polymer-NSAID conjugate. The polymer-NSAID conjugates comprise a substituted alkanoic acid non-steroidal anti-inflammatory drug (NSAID) conjugated to a biodegradable polymer backbone by an ester linkage.Type: GrantFiled: June 26, 2013Date of Patent: May 15, 2018Assignee: POLYACTIVA PTY LTDInventors: Asha Marina D'Souza, Andrew Craig Donohue, Russell John Tait, Florian Hans Maximilian Graichen, Sarah Man Yee Ng, Adrian Sulistio
-
Publication number: 20170216308Abstract: The present invention relates in general to polymer-bioactive agent conjugates for delivering a bioactive agent to a subject. The polymer-bioactive agent conjugates contain triazole moieties in the polymer backbone and a bioactive moiety selected from prostaglandin analogues, .beta.-blockers and mixtures thereof. The present invention also relates to methods for preparing the polymer conjugates using click chemical reactions, to monomer-bioactive agent conjugates suitable for preparing the polymer conjugates, and to pharmaceutical products comprising the polymer conjugates for the treatment of glaucoma.Type: ApplicationFiled: February 17, 2017Publication date: August 3, 2017Applicant: POLYACTIVA PTY LTDInventors: Sarah Man Yee Ng, Andrew Craig DONOHUE, Russell John TAIT, Stephen Lonsdale BIRKETT, Adrian SULISTIO, Anton BLENCOWE
-
Publication number: 20170182173Abstract: The present invention relates in general to polymer-bioactive agent conjugates for delivering a bioactive agent to a subject. The polymer-bioactive agent conjugates contain triazole moieties in the polymer backbone and a bioactive moiety comprising prostaglandin analogues. The present invention also relates to methods for preparing the polymer conjugates using click chemical reactions, to monomer-bioactive agent conjugates suitable for preparing the polymer conjugates, and to pharmaceutical products comprising the polymer conjugates for the treatment of glaucoma.Type: ApplicationFiled: March 14, 2017Publication date: June 29, 2017Applicant: POLYACTIVA PTY LTDInventors: Sarah Man Yee Ng, Andrew Craig DONOHUE, Russell John TAIT, Stephen Lonsdale BIRKETT, Adrian SULISTIO, Anton BLENCOWE, Alan Naylor
-
Patent number: 9572892Abstract: The present invention relates in general to polymer-bioactive agent conjugates for delivering a bioactive agent to a subject. The polymer-bioactive agent conjugates contain triazole moieties in the polymer backbone and a bioactive moiety selected from prostaglandin analogs, ?-blockers and mixtures thereof. The present invention also relates to methods for preparing the polymer conjugates using click chemical reactions, to monomer-bioactive agent conjugates suitable for preparing the polymer conjugates, and to pharmaceutical products comprising the polymer conjugates for the treatment of glaucoma.Type: GrantFiled: March 7, 2014Date of Patent: February 21, 2017Assignee: POLYACTIVA PTY LTDInventors: Sarah Man Yee Ng, Andrew Craig Donohue, Russell John Tait, Stephen Lonsdale Birkett, Adrian Sulistio, Anton Blencowe
-
Patent number: 9233934Abstract: The present invention relates to phenyl amino pyrimidine compounds which are inhibitors of protein kinases including JAK kinases. In particular the compounds are selective for JAK2 kinases. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.Type: GrantFiled: June 7, 2013Date of Patent: January 12, 2016Assignee: YM BIOSCIENCES AUSTRALIA PTY LTDInventors: Christopher John Burns, Andrew Craig Donohue, John Thomas Feutrill, Thao Lien Thi Nguyen, Andrew Frederick Wilks, Jun Zeng
-
Publication number: 20160000929Abstract: The presentinvention relates in general to polymer-bioactive agent conjugates for delivering a bioactive agent to a subject. The polymer-bioactive agent conjugates contain triazole moieties in the polymer backbone and a bioactive moiety selected from prostaglandin analogues, ?-blockers and mixtures thereof. The present invention also relates to methods for preparing the polymer conjugates using click chemical reactions, to monomer-bioactive agent conjugates suitable for preparing the polymer conjugates, and to pharmaceutical products comprising the polymer conjugates for the treatment of glaucoma.Type: ApplicationFiled: March 7, 2014Publication date: January 7, 2016Applicant: POLYACTIVA PTY LTDInventors: Sarah Man Yee NG, Andrew Craig DONOHUE, Russell John TAIT, Stephen Lonsdale BIRKETT, Adrian SULISTIO, Anton BLENCOWE
-
Publication number: 20150150999Abstract: The invention relates to polymer-drug conjugate for delivering a substituted alkanoic acid non-steroidal anti-inflammatory drug (NSAID). The invention also relates to drug delivery systems comprising the polymer-NSAID conjugate. The polymer-NSAID conjugates comprise a substituted alkanoic acid non-steroidal anti-inflammatory drug (NSAID) conjugated to a biodegradable polymer backbone by an ester linkage.Type: ApplicationFiled: June 26, 2013Publication date: June 4, 2015Inventors: Asha Marina D'Souza, Andrew Craig Donohue, Russell John Tait, Florian Hans Maximilian Graichen, Sarah Man Yee Ng, Adrian Sulistio